ArticleTranslational cancer research2026
A nomogram to predict disease-free survival in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy based on clinicopathological and sonographic features.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and verification of a prognostic nomogram model for triple-negative breast cancer patients with neoadjuvant therapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with triple-negative breast cancer (TNBC) who failed to achieve pathological complete response after neoadjuvant chemotherapy (NAC) may have a poorer prognosis. This study aimed to explore the factors associated with the adverse outcomes of these patients, and to develop a nomogram model for predicting disease-free survival (DFS). Methods: Patients diagnosed with TNBC at our institution between 2013 and 2022 were retrospectively evaluated. Clinicopathological and sonographic features associated with DFS were identified through multivariate Cox regression analysis to establish a nomogram model. The predictive performance of the nomogram model was assessed using receiver operating characteristic (ROC) curves and calibration curves. Results: A total of 103 TNBC patients with residual lesions following NAC were included in this study, with 15 cases (14.6%) experiencing DFS events. Multivariate analysis revealed that the pathological type of non-invasive ductal carcinoma [hazard ratio (HR) =7.741, 95% confidence interval (CI): 1.928-31.081, P=0.004], lymph node involvement (HR =3.455, 95% CI: 1.152-10.359, P=0.027), and the presence of a hyperechoic halo on ultrasound images (HR =4.43, 95% CI: 1.164-16.852, P=0.029) were independent prognostic factors associated with poor DFS. Patients with multiple risk factors exhibited worse survival outcomes. The areas under the ROC curve for predicting 2-, 3-, 4-, and 5-year DFS rates in the nomogram model were 0.767, 0.786, 0.785, and 0.739, respectively. The calibration curves demonstrated excellent consistency between the nomogram-predicted and actual survival probabilities. Conclusions: Our study developed a nomogram model to predict poor survival outcomes in TNBC patients with residual lesions after NAC, which may provide guidance for treatment strategies in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.